ArticleAbdominal radiology (New York)2026
Added diagnostic value of pseudocapsule and ADC heterogeneity beyond ccLS v2.0 in small renal masses.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify which multiparametric MRI parameters provide independent diagnostic value for clear cell renal cell carcinoma (ccRCC) beyond the clear cell likelihood score (ccLS) version 2.0 in small renal masses (SRMs), and to determine whether their addition improves discriminative performance.
methodsThis retrospective single-center study included patients with surgically confirmed SRMs (≤ 4 cm, > 25% enhancing component, no macroscopic fat) who underwent preoperative 1.5 T multiparametric MRI between September 2021 and May 2025. Two blinded radiologists of differing experience independently assigned ccLS v2.0 and evaluated qualitative and quantitative MR features. Univariate and multivariate logistic regression identified independent predictors; ROC analysis with the DeLong test assessed the added value of an augmented model over ccLS alone, with calibration and decision-curve analysis. Inter-reader agreement was quantified using Cohen's κ, quadratic-weighted κ, and the intraclass correlation.
resultsOf 817 patients, 108 eligible SRMs (64 ccRCC) across 102 patients were analyzed. At a cutoff of ≥ 4, ccLS v2.0 yielded AUCs of 0.837 (Reader 1) and 0.834 (Reader 2). On multivariate analysis with ccLS entered as a covariate, pseudocapsule and normalized ADC standard deviation (nADCsd) were the independent predictors of ccRCC in both readers, with pseudocapsule the strongest binary predictor (OR 6.96, p = 0.003; OR 4.25, p = 0.015). Adding pseudocapsule and nADCsd to the ccLS score significantly improved discrimination (Reader 1: AUC 0.905 vs. 0.837, p = 0.032; Reader 2: 0.882 vs. 0.834, p = 0.048); after bootstrap optimism correction, the improvement persisted (corrected AUC 0.890 and 0.872), with favorable calibration and net benefit on decision-curve analysis. Within the indeterminate ccLS = 3 subgroup, pseudocapsule was present in 100% and 90% of ccRCC lesions versus 22% and 31% of non-ccRCC lesions, and nADCsd was the only quantitative feature significant in both readers. Pseudocapsule showed excellent inter-reader agreement (κ = 0.862) and nADCsd good agreement (ICC 0.755).
conclusionPseudocapsule presence and nADCsd independently predicted ccRCC beyond ccLS v2.0 and provided significant added value, particularly in indeterminate ccLS = 3 lesions, pending multicenter validation.
Indexed as
Identifiers
42720763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.